Serum free light chain analysis

被引：33

作者：

Davids, Matthew S. ^{[1
,2
]}

Murali, Mandakolathur R. ^{[2
,3
]}

Kuter, David J. ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Hematol, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[3] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2010年 / 85卷 / 10期

关键词：

INDEPENDENT RISK-FACTOR; MONOCLONAL GAMMOPATHY; PROGRESSION; URINE; RATIO; IMMUNOFIXATION; AMYLOIDOSIS; REDUCTION; SURVIVAL; MARKERS;

D O I：

10.1002/ajh.21815

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In a variety of hematologic malignancies, immunoglobulin light chains (LC) are overproduced clonally and circulate without being linked by disulphide bonds to the immunoglobulin heavy chain. The recent development of a robust assay known as kappa and gamma "free'' LC (FLC) to quantify the levels of these unbound LC in the serum, and thereby determine their ratio, has led to an explosion of studies that demonstrate its utility in a wide range of hematologic disorders. This article summarizes laboratory testing for serum FLC, with a particular focus on clinical applications for the test. Am. J. Hematol. 85:787-790, 2010. (C) 2010 Wiley-Liss, Inc.

引用

页码：787 / 790

页数：4

共 50 条

[41] Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis
Usnarska-Zubkiewicz, Lidia
Holojda, Jadwiga
Debski, Jakub
Zubkiewicz-Zarebska, Anna
Zagocka, Ewa
Kuliczkowski, Kazimierz
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 23 (04): : 531 - 538
[42] Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect
Shaheen, Saad P.
Levinson, Stanley S.
CLINICA CHIMICA ACTA, 2009, 406 (1-2) : 162 - 166
[43] Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies High False-Positive Rate
Singh, Gurmukh
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 146 (02) : 207 - 214
[44] Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Ozkurt, Zuebeyde Nur
Sucak, Gulsan Tuerkoez
Aki, Sahika Zeynep
Yagci, Munci
Haznedar, Rauf
CANCER INVESTIGATION, 2017, 35 (03) : 195 - 201
[45] RECOMMENDATIONS FOR USE OF FREE LIGHT CHAIN ASSAY IN MONOCLONAL GAMMOPATHIES
Radovic, Vesna V.
JOURNAL OF MEDICAL BIOCHEMISTRY, 2010, 29 (01) : 1 - 8
[46] Limitations of Free Light Chain Assays caused by the Matrix Effect
Farnsworth, Christopher W.
Logsdon, Nicole M.
Hayes, Jennifer E.
Rais, Rehan
Willrich, Maria A.
Gronowski, Ann M.
JOURNAL OF APPLIED LABORATORY MEDICINE, 2020, 5 (02) : 311 - 319
[47] Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
Larsen, J. T.
Kumar, S. K.
Dispenzieri, A.
Kyle, R. A.
Katzmann, J. A.
Rajkumar, S. V.
LEUKEMIA, 2013, 27 (04) : 941 - 946
[48] Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy
Gueneta, L.
Decaux, O.
Lechartier, H.
Roperta, M.
Grosbois, B.
REVUE DE MEDECINE INTERNE, 2007, 28 (10): : 689 - 697
[49] Prognostic value of serum free light chain at diagnosis of multiple myeloma
Phan Nguyen Thanh Van
Cao Thi Loc
MEDICAL SCIENCE, 2022, 26 (123)
[50] Quantification of serum free light chain kappa and lambda by the SPAPLUS analyser
Maisin, Diane
Lepoutre, Thibault
Gruson, Damien
Wallemacq, Pierre
CLINICAL BIOCHEMISTRY, 2013, 46 (7-8) : 622 - 626

← 1 2 3 4 5 →